S3C3:Pharmaceutical Labeling

原文始发于微信公众号(化学音乐文化):S3C3:Pharmaceutical Labeling

S3C3:Pharmaceutical Labeling

JanFourman,PhD, EdD,MBA, MSRA

S3C3:Pharmaceutical Labeling

Eli Lilly – Pharma registration for diabetes/endocrine, women/men’s health, neural science, oncology, bone/muscle/joint therapeutic areas – 5 years
Eli Lilly – Pharmacovigilance – 7 years
Eli Lilly – Regulatory Intelligence – 3 Years
Purdue University and Roche Diagnostics – Teaching global pharma development, Africa and US
Consultant for Indiana Technical Assistance Program
Invited conference speaker
Published author

S3C3:Pharmaceutical Labeling
S3C3:Pharmaceutical Labeling


Pharmaceutical Labeling

Part 1 – Summary of Labeling Requirements


General Labeling Requirements (CFR 201 Subparts A and B)

Electronic Labeling

Package Insert:

Physician’s Labeling Rule (PLR)

Medication Guides

Label Changes

Part 2 – Advertising and PromotionNo Preapproval Promotion

Material Submission and Preclearance

Substantial Evidence Standard

Fair Balance

Non-print Promotion

Part 3 – Serialization

Drug Supply Chain Security Act (DSCSA):


Product Tracing

Authorized Trading Partners

Suspect Products

Product Identification


打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2020年2月18日 12:25
下一篇 2020年2月18日 12:31